Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...
Michael J. Fox has spent decades navigating Parkinson’s disease while continuing to shape the conversations about the ...
MedPage Today on MSN
Parkinson's disease gets new treatment approved
FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...
Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.
Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.
Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA ...
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...
A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results